Literature DB >> 20442442

Novel drugs for the treatment of multiple myeloma.

Joan Bladé, Ma Teresa Cibeira, Laura Rosiñol.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20442442      PMCID： PMC2864373          DOI： 10.3324/haematol.2009.021550

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  25 in total

1.  Impact of complete remission with intensive therapy in patients with responsive multiple myeloma.

Authors:  R Alexanian; D Weber; S Giralt; M Dimopoulos; K Delasalle; T Smith; R Champlin
Journal:  Bone Marrow Transplant       Date:  2001-05       Impact factor: 5.483

2.  Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells.

Authors:  Frank Wischnewski; Klaus Pantel; Heidi Schwarzenbach
Journal:  Mol Cancer Res       Date:  2006-05       Impact factor: 5.852

3.  Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

Authors:  Jean-Luc Harousseau; Michel Attal; Xavier Leleu; Jacques Troncy; Brigitte Pegourie; Anne-Marie Stoppa; Cyrille Hulin; Lofti Benboubker; Jean-Gabriel Fuzibet; Marc Renaud; Philippe Moreau; Hervé Avet-Loiseau
Journal:  Haematologica       Date:  2006-10-17       Impact factor: 9.941

4.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

Review 5.  Cancer/testis antigens, gametogenesis and cancer.

Authors:  Andrew J G Simpson; Otavia L Caballero; Achim Jungbluth; Yao-Tseng Chen; Lloyd J Old
Journal:  Nat Rev Cancer       Date:  2005-08       Impact factor: 60.716

6.  Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.

Authors:  Sally K Martin; Peter Diamond; Sharon A Williams; Luen Bik To; Daniel J Peet; Nobutaka Fujii; Stan Gronthos; Adrian L Harris; Andrew C W Zannettino
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

7.  Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.

Authors:  Djordje Atanackovic; York Hildebrandt; Adam Jadczak; Yanran Cao; Tim Luetkens; Sabrina Meyer; Sebastian Kobold; Katrin Bartels; Caroline Pabst; Nesrine Lajmi; Maja Gordic; Tanja Stahl; Axel R Zander; Carsten Bokemeyer; Nicolaus Kröger
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

8.  Extramedullary multiple myeloma escapes the effect of thalidomide.

Authors:  Laura Rosiñol; Ma Teresa Cibeira; Joan Bladé; Jordi Esteve; Marta Aymerich; María Rozman; Marta Segarra; Maria C Cid; Xavier Filella; Emili Montserrat
Journal:  Haematologica       Date:  2004-07       Impact factor: 9.941

9.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Authors:  Donna M Weber; Christine Chen; Ruben Niesvizky; Michael Wang; Andrew Belch; Edward A Stadtmauer; David Siegel; Ivan Borrello; S Vincent Rajkumar; Asher Alban Chanan-Khan; Sagar Lonial; Zhinuan Yu; John Patin; Marta Olesnyckyj; Jerome B Zeldis; Robert D Knight
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

10.  High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission.

Authors:  E Nadal; E Giné; J Bladé; J Esteve; L Rosiñol; F Fernández-Avilés; P Marin; C Martinez; M Rovira; A Urbano-Ispizua; E Carreras; E Montserrat
Journal:  Bone Marrow Transplant       Date:  2004-01       Impact factor: 5.483
View more
  1 in total

1.  Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial.

Authors:  Damai Santosa; Catharina Suharti; Ignatius Riwanto; Edi Dharmana; Eko Adhi Pangarsa; Budi Setiawan; Suyono Suyono; Mika Lumban Tobing; Suhartono Suhartono; Soeharyo Hadisapurto
Journal:  Caspian J Intern Med       Date:  2022
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.